Synergistic antitumor effect of shRNA knock-down PD-1 combined with CD30-CAR-T

To study the antitumor effect of CD30-CAR-T combined with shRNA knocking PD-1, a sequence was select in vitro that PD-1 knock-down by 50%. In vitro treatment of Hodgkin’s lymphoma by lentiviral vector carrying PD-1 interfering RNA combined with CD30-CAR protein. Experimental results show that the PD-1 on low and the increase of the CD30-CAR protein can inhibit the T cells proliferation and the influence of the CD30-CAR protein more significantly. In parallel, experiments confirmed that CD30-CAR-T cells had a specific targeted and lysis effect on L428, while PD-1 knock-down inhibited its killing effect to a certain extent. Therefore, experiments suggest that CD30-CAR-T combined with PD-1 interfering RNA may not be suitable for anti-tumor therapy.